These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35060433)

  • 1. How accurate are the longer-term projections of overall survival for cancer immunotherapy for standard versus more flexible parametric extrapolation methods?
    Cooper M; Smith S; Williams T; Aguiar-Ibáñez R
    J Med Econ; 2022; 25(1):260-273. PubMed ID: 35060433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
    Bullement A; Meng Y; Cooper M; Lee D; Harding TL; O'Regan C; Aguiar-Ibanez R
    J Med Econ; 2019 Mar; 22(3):205-214. PubMed ID: 30422080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
    Federico Paly V; Kurt M; Zhang L; Butler MO; Michielin O; Amadi A; Hernlund E; Johnson HM; Kotapati S; Moshyk A; Borrill J
    MDM Policy Pract; 2022; 7(1):23814683221089659. PubMed ID: 35356551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.
    Chaudhary MA; Edmondson-Jones M; Baio G; Mackay E; Penrod JR; Sharpe DJ; Yates G; Rafiq S; Johannesen K; Siddiqui MK; Vanderpuye-Orgle J; Briggs A
    Med Decis Making; 2023 Jan; 43(1):91-109. PubMed ID: 36259353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing Survival Extrapolation within All-Cause and Relative Survival Frameworks by Standard Parametric Models and Flexible Parametric Spline Models Using the Swedish Cancer Registry.
    Chen EY; Leontyeva Y; Lin CN; Wang JD; Clements MS; Dickman PW
    Med Decis Making; 2024 Apr; 44(3):269-282. PubMed ID: 38314657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study.
    Bullement A; Latimer NR; Bell Gorrod H
    Value Health; 2019 Mar; 22(3):276-283. PubMed ID: 30832965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the Performance of Alternative Methods for Estimating Long-Term Survival Benefit of Immuno-oncology Therapies.
    Monnickendam G
    Value Health; 2024 Jun; 27(6):746-754. PubMed ID: 38428815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma.
    Klijn SL; Fenwick E; Kroep S; Johannesen K; Malcolm B; Kurt M; Kiff C; Borrill J
    Pharmacoeconomics; 2021 Mar; 39(3):345-356. PubMed ID: 33428174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection.
    Bullement A; Willis A; Amin A; Schlichting M; Hatswell AJ; Bharmal M
    BMC Med Res Methodol; 2020 May; 20(1):103. PubMed ID: 32375680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer.
    Gray J; Sullivan T; Latimer NR; Salter A; Sorich MJ; Ward RL; Karnon J
    Med Decis Making; 2021 Feb; 41(2):179-193. PubMed ID: 33349137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities.
    Grumberg V; Roze S; Chevalier J; Borrill J; Gaudin AF; Branchoux S
    Int J Technol Assess Health Care; 2022 Mar; 38(1):e28. PubMed ID: 35331347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: Evidence from a Systematic Literature Review.
    Sussman M; Crivera C; Benner J; Adair N
    Adv Ther; 2021 Aug; 38(8):4178-4194. PubMed ID: 34251651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma.
    Bakker LJ; Thielen FW; Redekop WK; Groot CU; Blommestein HM
    BMC Med Res Methodol; 2023 May; 23(1):132. PubMed ID: 37248477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1.
    Vadgama S; Mann J; Bashir Z; Spooner C; Collins GP; Bullement A
    Value Health; 2022 Jun; 25(6):1010-1017. PubMed ID: 35667774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges with Estimating Long-Term Overall Survival in Extensive Stage Small-Cell Lung Cancer: A Validation-Based Case Study.
    Johal S; Brannman L; Genestier V; Cawston H
    Clinicoecon Outcomes Res; 2024; 16():97-109. PubMed ID: 38433888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity.
    Grant TS; Burns D; Kiff C; Lee D
    Pharmacoeconomics; 2020 Apr; 38(4):385-395. PubMed ID: 31848900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.
    Sweeting MJ; Rutherford MJ; Jackson D; Lee S; Latimer NR; Hettle R; Lambert PC
    Med Decis Making; 2023 Aug; 43(6):737-748. PubMed ID: 37448102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations.
    Ouwens MJNM; Mukhopadhyay P; Zhang Y; Huang M; Latimer N; Briggs A
    Pharmacoeconomics; 2019 Sep; 37(9):1129-1138. PubMed ID: 31102143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating the loss of lifetime function using flexible parametric relative survival models.
    Jakobsen LH; Andersson TM; Biccler JL; El-Galaly TC; Bøgsted M
    BMC Med Res Methodol; 2019 Jan; 19(1):23. PubMed ID: 30691400
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.